Compendium of Cancer Genome Aberrations

STBT5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(2 intermediate revisions by 2 users not shown)
Line 267: Line 267:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Fibrous_hamartoma_of_infancy|Fibrous hamartoma of infancy]]
|[[STBT5:Fibrous_hamartoma_of_infancy|Fibrous hamartoma of infancy]]
Line 377: Line 386:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Cellular_angiofibroma|Cellular angiofibroma]]
|[[STBT5:Cellular_angiofibroma|Cellular angiofibroma]]
Line 487: Line 505:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|[[STBT5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
Line 547: Line 574:
|Katie Schieffer
|Katie Schieffer
|4/21/2025
|4/21/2025
|
|10/1/2025
|PENDING
|PENDING
|
|
Line 597: Line 624:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Tenosynovial_giant_cell_tumour|Tenosynovial giant cell tumour]]
|[[STBT5:Tenosynovial_giant_cell_tumour|Tenosynovial giant cell tumour]]
Line 707: Line 743:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Lymphangioma_and_lymphangiomatosis|Lymphangioma and lymphangiomatosis]]
|[[STBT5:Lymphangioma_and_lymphangiomatosis|Lymphangioma and lymphangiomatosis]]
Line 817: Line 862:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Myopericytoma,_including_myofibroma|Myopericytoma, including myofibroma]]
|[[STBT5:Myopericytoma,_including_myofibroma|Myopericytoma, including myofibroma]]
Line 927: Line 981:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Spindle_cell_/_sclerosing_rhabdomyosarcoma|Spindle cell / sclerosing rhabdomyosarcoma]]
|[[STBT5:Spindle_cell_/_sclerosing_rhabdomyosarcoma|Spindle cell / sclerosing rhabdomyosarcoma]]
Line 1,037: Line 1,100:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Solitary_circumscribed_neuroma|Solitary circumscribed neuroma]]
|[[STBT5:Solitary_circumscribed_neuroma|Solitary circumscribed neuroma]]
Line 1,147: Line 1,219:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Angiomatoid_fibrous_histiocytoma|Angiomatoid fibrous histiocytoma]]
|[[STBT5:Angiomatoid_fibrous_histiocytoma|Angiomatoid fibrous histiocytoma]]
Line 1,218: Line 1,299:
|James Solomon, MD, PhD
|James Solomon, MD, PhD
|2/20/2022
|2/20/2022
|
|12/9/2025
|PENDING
|PENDING
|
|
|Alanna Church
|Katie Schieffer
|
|
|
|
Line 1,268: Line 1,349:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Extraskeletal_myxoid_chondrosarcoma_|Extraskeletal myxoid chondrosarcoma]]
|[[STBT5:Extraskeletal_myxoid_chondrosarcoma_|Extraskeletal myxoid chondrosarcoma]]
Line 1,360: Line 1,450:
|Sadeem Qdaisat
|Sadeem Qdaisat
|10/1/23
|10/1/23
|
|12/9/2025
|PENDING
|PENDING
|
|
Line 1,399: Line 1,489:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|
|
Line 1,541: Line 1,640:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Central_chondrosarcoma,_grades_2_and_3|Central chondrosarcoma, grades 2 and 3]]
|[[STBT5:Central_chondrosarcoma,_grades_2_and_3|Central chondrosarcoma, grades 2 and 3]]
Line 1,651: Line 1,759:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Osteosarcoma|Osteosarcoma]]
|[[STBT5:Osteosarcoma|Osteosarcoma]]
Line 1,761: Line 1,878:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Angiosarcoma_of_bone|Angiosarcoma of bone]]
|[[STBT5:Angiosarcoma_of_bone|Angiosarcoma of bone]]
Line 1,871: Line 1,997:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Adamantinoma_of_long_bones|Adamantinoma of long bones]]
|[[STBT5:Adamantinoma_of_long_bones|Adamantinoma of long bones]]
Line 1,981: Line 2,116:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Langerhans_cell_histiocytosis_|Langerhans cell histiocytosis]]
|[[STBT5:Langerhans_cell_histiocytosis_|Langerhans cell histiocytosis]]
Retrieved from "https://test.ccga.io/index.php/STBT5:Volunteer_Assignments_and_Opportunities"